Whether you are developing a new drug formulation, a novel delivery system, or an improved dosage form, the way your patent application is prepared and the evidence you provide can determine whether protection is granted or refused. This page explains what can be patented in the pharmaceutical space, the challenges you are likely to encounter, and how to build the strongest possible application.
What pharmaceutical inventions can be patented?
Patent protection is available for a wide range of pharmaceutical inventions, provided they meet the standard requirements of novelty, inventive step, and sufficient disclosure. The most common categories include:
- New chemical entities — novel active pharmaceutical ingredients (APIs) that have not previously been disclosed
- Formulations and compositions — combinations of active and inactive ingredients designed to achieve a particular therapeutic effect, stability profile, or release characteristic
- Dosage forms — tablets, capsules, transdermal patches, injectables, inhalers, and other forms through which a drug is administered
- Drug delivery systems — controlled-release mechanisms, targeted delivery technologies, nanoparticle carriers, and similar innovations that improve how a drug reaches its site of action
- Methods of treatment — new therapeutic uses for known compounds, including second medical use claims where an existing drug is found to treat a different condition
- Manufacturing processes — novel methods for synthesising, purifying, or producing pharmaceutical substances
- Salts, polymorphs, and crystalline forms — specific physical forms of an active ingredient that offer improved stability, bioavailability, or processability
The scope of what can be patented is broad, but the strength of your application will depend heavily on how the invention is characterised and what supporting evidence is provided. This is where pharmaceutical patents differ significantly from many other technology areas.
The "mere admixture" objection
One of the most common challenges faced by pharmaceutical patent applications — particularly those claiming formulations or compositions — is the "mere admixture" objection.
When a patent claim describes a combination of ingredients, an examiner may argue that the combination is simply an aggregation of known components, each contributing only its expected properties. In other words, if ingredient A is known to do X, and ingredient B is known to do Y, a combination that does both X and Y is not considered inventive — it is merely an admixture.
To overcome a mere admixture objection, the applicant must demonstrate that the combination produces effects beyond the sum of its known parts — typically through synergistic interaction or unexpected results.
Successfully overcoming this objection usually requires demonstrating one or more of the following:
- Synergistic effects — the ingredients interact to produce a combined effect that is greater than what would be expected from the individual contributions of each component
- Unexpected results — the combination achieves a result that a skilled person would not have predicted, such as improved stability, enhanced bioavailability, or a reduction in side effects
- Comparative data — test results comparing the claimed formulation against its individual components, or against the closest prior art formulation, to quantify the improvement
This is why the preparation of a pharmaceutical patent application often involves more than simply describing the formulation. The specification should, where possible, include experimental data, comparative studies, and a clear articulation of why the combination is more than the sum of its parts. For a broader discussion of formulation patentability, see our page on what can be patented.
Why thorough disclosure matters
Pharmaceutical patent applications are subject to particularly close scrutiny during examination. Examiners and, in some cases, opponents will examine whether the specification provides sufficient detail for a person skilled in the field to reproduce the invention without undue experimentation.
For pharmaceutical inventions, this means the specification should clearly describe:
- The precise composition, including the identity and proportions of each ingredient
- The method of preparation, including processing conditions that affect the final product
- The functional properties of the formulation, including how and why it works
- Supporting experimental data that demonstrates the claimed advantages
Insufficient disclosure is a ground for refusal during examination and a ground for revocation after grant. In the pharmaceutical field, where competitors are often well-resourced and highly motivated to challenge patents, thorough disclosure from the outset is essential to building a defensible patent.
Patent term extensions
Under the Australian Patents Act, a patent term extension (PTE) of up to five years may be available for pharmaceutical patents, potentially extending the maximum term from 20 years to 25 years. The PTE mechanism was designed to compensate patent holders for the time lost during the regulatory approval process — the period between filing a patent and receiving approval from the Therapeutic Goods Administration (TGA) to market the product.
To be eligible for a PTE, the patent must disclose and claim a pharmaceutical substance per se, and goods containing that substance must be included on the Australian Register of Therapeutic Goods (ARTG). It is important to note that recent case law has narrowed the scope of PTE eligibility. The Full Federal Court has confirmed that "pharmaceutical substance" in this context refers to the active ingredient that exerts the therapeutic effect — not a formulation, delivery system, or dosage form.
Patent term extensions in Australia apply to patents that claim the active pharmaceutical ingredient itself. Formulation patents are generally not eligible for extension under the current legal framework.
This distinction has significant implications for patent filing strategy. Where possible, it may be advisable to file separate patent applications covering both the active ingredient and the formulation, ensuring that the active ingredient patent is structured to qualify for a PTE if regulatory approval follows.
Data exclusivity as a complementary protection
In addition to patent protection, pharmaceutical innovators in Australia benefit from a five-year data exclusivity period. This prevents generic manufacturers from relying on the innovator's clinical trial data when seeking TGA approval for a competing product containing the same active ingredient.
Data exclusivity and patent protection serve different purposes and operate independently. A patent prevents competitors from making, using, or selling the patented invention. Data exclusivity prevents competitors from referencing your regulatory data to support their own approval application. Together, they form complementary layers of protection — but neither is a substitute for the other.
It is worth noting that data exclusivity in Australia is shorter than in some other jurisdictions. Strategic coordination of patent filing, regulatory submissions, and data exclusivity periods can help maximise the overall period of market protection.
Regulatory considerations and patent strategy
The pharmaceutical patent landscape is shaped by the interplay between patent law and regulatory requirements. An effective patent strategy in this field should consider:
- Filing timing — securing a priority date as early as possible, while ensuring sufficient supporting data is available for a robust specification
- Claim layering — building a patent portfolio that covers the active ingredient, key formulations, manufacturing methods, and specific therapeutic uses through separate applications where commercially justified
- International considerations — pharmaceutical patent requirements and enforcement mechanisms differ between jurisdictions, and a coordinated international filing strategy is essential for products with global market potential
- Freedom to operate — understanding the existing patent landscape to avoid infringing third-party rights before committing to product development
Get expert advice on your pharmaceutical invention
Pharmaceutical patents require precision in both the science and the legal drafting. The difference between a granted patent and a refused application often comes down to the quality of the specification, the strength of the supporting evidence, and the strategy behind the claims.
If you are developing a pharmaceutical invention and want to understand your options for patent protection, contact Patentec for a complimentary consultation. We can assess the patentability of your invention and recommend an approach tailored to your commercial and regulatory objectives.